Breaking News Instant updates and real-time market news.

AKTS

Akoustis

$8.25

0.04 (0.49%)

, BEAT

BioTelemetry

$42.15

1.87 (4.64%)

08:10
09/12/19
09/12
08:10
09/12/19
08:10

Lake Street to hold a conference

3rd Annual Best Ideas Growth (BIG 3) Conference will be held in New York on September 12.

AKTS

Akoustis

$8.25

0.04 (0.49%)

BEAT

BioTelemetry

$42.15

1.87 (4.64%)

BIOS

BioScrip

$3.31

0.09 (2.80%)

CKPT

Checkpoint Therapeutics

$3.03

0.29 (10.58%)

HIIQ

Health Insurance Innovations

$19.90

1.25 (6.70%)

NVEE

NV5 Global

$72.00

3.07 (4.45%)

HEAR

Turtle Beach

$9.62

-0.18 (-1.84%)

GTLS

Chart Industries

$67.76

1.625 (2.46%)

NDRA

Endra Life Sciences

$1.72

0.03 (1.78%)

LTRX

Lantronix

$3.42

-0.355 (-9.40%)

REED

Reed's

$1.65

-0.04 (-2.37%)

RIBT

RiceBran

$2.67

0.02 (0.75%)

RST

Rosetta Stone

$19.64

0.95 (5.08%)

TRUP

Trupanion

$26.87

1.58 (6.25%)

TLRA

Telaria

$9.94

0.14 (1.43%)

ZIOP

Ziopharm

$4.92

0.15 (3.14%)

WPRT

Westport

$3.03

0.18 (6.32%)

SONM

Sonim

$3.75

(0.00%)

PERI

Perion Network

$5.33

0.03 (0.57%)

PFIE

Profire Energy

$1.66

0.07 (4.40%)

INTT

inTEST

$4.55

-0.02 (-0.44%)

HSC

Harsco

$20.07

1.22 (6.47%)

OCX

OncoCyte

$1.79

0.11 (6.55%)

SHSP

SharpSpring

$11.84

0.01 (0.08%)

SLGG

Super League Gaming

$4.75

0.395 (9.08%)

  • 12

    Sep

  • 12

    Sep

  • 17

    Sep

  • 17

    Sep

  • 18

    Sep

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 01

    Oct

  • 01

    Oct

  • 02

    Oct

  • 13

    Nov

AKTS Akoustis
$8.25

0.04 (0.49%)

08/27/19
PIPR
08/27/19
NO CHANGE
Target $10
PIPR
Overweight
Akoustis thesis intact after business update call, says Piper Jaffray
Piper Jaffray analyst Harsh Kumar says his Overweight thesis on shares of Akoustis Technologies is intact following the company's business update call. Akoustis provided preliminary June quarter revenue of $569,000, which is above the analyst's $509,000 estimate. Further, management provided September quarter revenue guidance of roughly flat sequential growth, as a 50% quarter-over-quarter increase in filter revenue offsets the company winding down its MEMS foundry business, Kumar tells investors in a research note. Overall, he believes Akoustis remains on-track and reiterates an Overweight rating on the shares with a $10 price target.
07/10/19
NORL
07/10/19
UPGRADE
NORL
Outperform
Akoustis upgraded to Outperform from Market Perform at Northland
07/10/19
NORL
07/10/19
UPGRADE
Target $7.4
NORL
Outperform
Northland says Akoustis at inflection point, upgrades to Outperform
As previously reported, Northland analyst Gus Richard upgraded Akoustis to Outperform from Market Perform, stating that the company is at an inflection point as it starts to ship trial quantities of BAW filters for WiFi routers. He keeps a $7.40 price target on Akoustis shares.
05/13/19
OPCO
05/13/19
NO CHANGE
Target $10
OPCO
Outperform
Akoustis top line to continue accelerating, says Oppenheimer
Oppenheimer analyst Rick Schafer kept his Outperform rating and $10 price target on Akoustis after its Q3 results, saying that earnings were short of consensus, but some of the company's military sales had been pushed out to Q4. The analyst notes that investor focus falls on the company's handset market, which is Akoustis' "top volume opportunity," and expects its top line to accelerate as Akoustis translates order wins into revenues.
BEAT BioTelemetry
$42.15

1.87 (4.64%)

07/31/19
LSCM
07/31/19
NO CHANGE
Target $90
LSCM
Buy
BioTelemetry has 'significant opportunities' for growth, says Lake Street
Lake Street analyst Brooks O'Neil affirms a Buy rating on BioTelemetry with a $90 price target after the company reported "another productive quarter." The analyst remains confident the management team will continue to execute. He likes the profitable core cardiac monitoring business at BioTelemetry and sees "significant opportunities" for accelerating organic growth in Geneva, research services, and population health.
08/02/19
RAJA
08/02/19
DOWNGRADE
RAJA
Market Perform
BioTelemetry downgraded to Market Perform from Outperform at Raymond James
08/02/19
08/02/19
DOWNGRADE

Market Perform
BioTelemetry downgraded to Market Perform on moderating growth at Raymond James
As previously reported, Raymond James downgrade BioTelemetry (BEAT) to Market Perform from Outperform. Analyst Jayson Bedford has increased concerns around market share loss and BioTelemetry's growth profile following slower Q2 organic growth announced earlier this week and competitor iRythm's (IRTC) strong results. Bedford said the margin structure is already "optimized" and the company lacks identifiable new growth drivers to drive shares higher.
07/09/19
BNCH
07/09/19
NO CHANGE
BNCH
Alibaba, Take-Two among Benchmark's Best Ideas for second half
Benchmark's analyst team laid out their Best Ideas for the second half of 2019, naming Alibaba (BABA), Take-Two (TTWO), BioTelemetry (BEAT), Biofrontera (BFRA), Chembio Diagnostics (CEMI), Ctrip (CTRP), Green Thumb Industries (GTBIF), II-VI (IIVI), LivePerson (LPSN), Nanometrics (NANO), Nexstar (NXST), Pegasystems (PEGA), Tabula Rasa HealthCare (TRHC) and Waitr Holdings (WTRH) to their list.
BIOS BioScrip
$3.31

0.09 (2.80%)

08/05/19
LSCM
08/05/19
NO CHANGE
Target $4.5
LSCM
Buy
BioScrip not the acquirer in merger, which is positive, says Lake Street
Lake Street analyst Brooks O'Neil says he learned recently from talking with Option Care CFO Mike Shapiro that Option Care will be deemed the acquirer of BioScrip. The analyst previously thought BioScrip would be the acquirer, and he views this new development as a positive for the shares. BioScrip being added on top of historical Option Care will accelerate revenue growth and margins will go up, O'Neil tells investors in a research note. "Those two things are likely to be well received by investors," says the analyst, who expects this trend for "at least" the first five-to-six quarters post the combination. He affirms a Buy rating on BioScrip with a $4.50 price target.
07/15/19
LSCM
07/15/19
NO CHANGE
Target $4.5
LSCM
Buy
CMS funding potential 'meaningful positive' for BioScrip, says Lake Street
The Centers for Medicare & Medicaid Services last week included in its budget proposal funding for the new Medicare home infusion benefit for 2021, Lake Street analyst Brooks O'Neil tells investors in a research note. The Cures Act in 2016 created the benefit for all eligible seniors, and now CMS is acknowledging it exists and providing funding for it in the Medicare budget, adds the analyst. He believes this is a potentially "meaningful positive" for BioScrip as Medicare currently does not reimburse for home infusion services and the senior population will likely become a heavy user of such services. O'Neil affirms a Buy rating on the shares with a $4.50 price target.
03/18/19
03/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Needham with analyst Laura Martin citing three factors that she sees creating a "negative network effect," namely its strategic pivot toward privacy and encrypted messages, the growing risks of regulation and "horrific" events like those recently in New Zealand that hurt Facebook's brand and are difficult to block from the service at a 100% level. 2. Quest Diagnostics (DGX) downgraded to Neutral from Outperform at Credit Suisse. 3. Aramark (ARMK) downgraded to Neutral from Buy at Nomura Instinet with analyst Dan Dolev saying while the company's "significant scale" in North America should drive consistent 5%-plus organic growth, "execution mishaps and inability to win sufficient new business" resulted in just 2%-3% organic growth versus 7%-8% for main competitor Compass. 4. BioScrip (BIOS) downgraded to Equal Weight from Overweight at Stephens with analyst Dana Hambly saying the company "surprised the market" by announcing a merger with Option Care. 5. PVH Corp. (PVH) assumed with a Neutral from Buy at Citi with analyst Paul Lejuez saying while PVH has two brands with good global growth potential in Tommy Hilfiger and Calvin Klein, the company overall is still heavily dependent on the North America wholesale and outlet channels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/18/19
ADAM
03/18/19
NO CHANGE
Target $3.5
ADAM
Buy
Canaccord, while disappointed with merger terms, remains buyer of BioScrip
Canaccord Genuity analyst Richard Close lowered his price target for BioScrip to $3.50 from $5.00 while reiterating a Buy rating on the shares. While disappointed with the terms of the Option Care merger agreement as BioScrip shareholders are just 20% shareholders post-transaction, the analyst says he understands the rationale for the merger. The need for scale in healthcare is "increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close tells investors in a research note titled "Merger: short-term pain but long-term." Longer-term scale matters and the transaction provides an improved capital structure, says the analyst. He remains a buyer of BioScrip shares.
CKPT Checkpoint Therapeutics
$3.03

0.29 (10.58%)

05/01/19
HCWC
05/01/19
NO CHANGE
Target $15
HCWC
Buy
Checkpoint Therapeutics price target raised to $15 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Checkpoint Therapeutics to $15 from $11 after the company announced its first data release from the ongoing Phase 1 with cosibelimab, its anti-PD-L1 asset. The data release is "quite impressive" based on the efficacy and safety profile of cosibelimab, Pantginis tells investors in a research note. He believes these data "represent an important tipping point for investors" as they assess cosibelimab's potential. Further, the analyst also projects "another overnight transformation on the business development front." He keeps a Buy rating on Checkpoint.
05/29/19
LSCM
05/29/19
INITIATION
Target $12
LSCM
Buy
Lake Street starts Checkpoint Therapeutics with Buy rating, $12 target
Lake Street analyst Thomas Flaten initiated coverage of Checkpoint Therapeutics with a Buy rating and $12 price target. The company should initiate a pivotal study in its non-small cell lung cancer treatment, CK-101, by year-end 2019, Flaten tells investors in a research note. He sees potential for clinical differentiation and "disruptive" commercial strategies to drive "significant value" for Checkpoint.
05/29/19
LSCM
05/29/19
INITIATION
Target $12
LSCM
Buy
Checkpoint Therapeutics initiated with a Buy at Lake Street
Lake Street initiated Checkpoint Therapeutics with a Buy and $12 price target.
HIIQ Health Insurance Innovations
$19.90

1.25 (6.70%)

08/13/19
CANT
08/13/19
NO CHANGE
Target $80
CANT
Overweight
Health Insurance cash flow not major concern, says Cantor Fitzgerald
After reviewing Health Insurance Innovations' cash flow during the first half of 2019, Cantor Fitzgerald analyst Steven Halper is not that concerned about the company's use of cash. Excluding different items, the company generated free cash flow over the trailing 12 months, which makes the reported negative cash flow not a major concern, Halper tells investors in a research note. Looking ahead, it is entirely possible that Health Insurance will continue to use cash as it begins to build up its Medicare business, adds the analyst. However, he remains optimistic about its Medicare initiative, which he believes should enhance its valuation over time. Halper reiterates an Overweight rating on Health Insurance Innovations with an $80 price target.
08/06/19
CHLM
08/06/19
NO CHANGE
Target $50
CHLM
Buy
Health Insurance Innovations price target cut to $50 from $65 at Craig-Hallum
Craig-Hallum analyst George Sutton lowered his price target for Health Insurance Innovations to $50 from $65 following quarterly results and as he expects the stock to remain volatile going forward. The analyst reiterates a Buy rating on the shares given an attractive risk-reward scenario.
08/16/19
PIPR
08/16/19
NO CHANGE
Target $87
PIPR
Overweight
Teladoc short report selloff brings buying opportunity, says Piper Jaffray
Shares of Teladoc Health (TDOC) fell yesterday after a short report raised questions about the company's relationship with Health Insurance Innovations (HIIQ), Piper Jaffray analyst Sean Wieland tells investors in a research note. After speaking with Teladoc's CFO, the analyst believes the "drama is unwarranted," and he encourages investors to take advantage of "another buying opportunity." The CFO told Wieland that Health Insurance is a client of Teladoc under the "visits included" model, which means neither Health Insurance nor the member pay a fee each time the service is used. According to Teladoc, less than 1% of revenue and EBITDA is tied to Health Insurance Innovations, Wieland tells investors in a research note. He believes the short report is "flawed because it relies on inaccurate assumptions and slippery-slope logic." Wieland reiterates an Overweight rating on Teladoc with an $87 price target. The stock closed yesterday down 7.5%, or $4.56, to $56.94.
08/06/19
LSCM
08/06/19
NO CHANGE
Target $40
LSCM
Buy
Health Insurance Innovations price target lowered to $40 from $50 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Health Insurance Innovations to $40 from $50 and maintains a Buy rating on the shares following the company's Q2 results. Health Insurance is a "show me story" in transition as it aggressively moves away from short-duration plans and ramps up investments in other offerings, Argento tells investors in a research note.
NVEE NV5 Global
$72.00

3.07 (4.45%)

05/09/19
ROTH
05/09/19
NO CHANGE
Target $96
ROTH
Buy
NV5 Global price target raised to $96 from $90 at Roth Capital
Roth Capital analyst Jeff Martin raised his price target for NV5 Global to $96 from $90, citing continued execution on "strong" organic growth driven by cross selling discipline, coupled with accretive acquisitions that expand geographic reach and service capability. The analyst believes management's disciplined approach to M&A commands a premium valuation to peers. He reiterates a Buy rating on the shares.
03/08/19
ROTH
03/08/19
NO CHANGE
Target $90
ROTH
Buy
NV5 Global price target lowered to $90 from $97 at Roth Capital
Roth Capital analyst Jeff Martin maintained a Buy rating on NV5 Global but lowered his price target to $90 from $97 following the company's in line Q4 results. In a research note to investors, Martin says his investment thesis on NV5 centers around continued execution on strong organic growth, coupled with accretive acquisitions that expand geographic reach and service capability. He believes management's disciplined approach to M&A commands a premium valuation to peers and feels that fundamentals of the business are sound and that the material weakness is not a market-driving event.
03/08/19
MAXM
03/08/19
NO CHANGE
Target $93
MAXM
Buy
NV5 Global price target lowered to $93 from $110 at Maxim
Maxim analyst Tate Sullivan lowered his price target on NV5 Global after its Q1 earnings miss and its disclosure of accounting issues. The analyst is concerned with the company's slower conversion of backlog to revenue but keeps his Buy rating over the longer term. Sullivan attributes his positive stance to NV5 Global's regional infrastructure acquisition and integration strategy remaining intact, its rising free cash flows, and its low debt-to-EBITDA ratio.
08/08/19
ROTH
08/08/19
NO CHANGE
Target $91
ROTH
Buy
NV5 Global price target lowered to $91 from $96 at Roth Capital
Roth Capital analyst Jeff Martin lowered his price target for NV5 Global to $91 from $96 as he anticipates volatility will result in reaction to Q2 results and updated guidance, which could result in an attractive buying opportunity. The analyst believes fundamentals of the business remain "strong," particularly in the Energy division. He reiterates a Buy rating on the shares.
HEAR Turtle Beach
$9.62

-0.18 (-1.84%)

03/15/19
DADA
03/15/19
NO CHANGE
Target $23
DADA
Buy
Turtle Beach price target lowered to $23 from $26 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Turtle Beach to $23 from $26, saying that while its Q1 guidance and the pending acquisition of Roccat aimed to expand its product line were encouraging, its FY19 earnings outlook was disappointing. Excluding the $20M-$24M in revenue contribution from Roccat, the analyst sees the management's $220M-$224M outlook implying a 22%-24% decline, which is worse than his expected 10% slowdown and the initial consensus calling for a 15% slide. Forte is calling the outlook as overly conservative however and keeps his Buy rating on Turtle Beach given its "accelerating refresh cycle and more freemium title releases such as Apex Legends."
05/09/19
DADA
05/09/19
NO CHANGE
Target $26
DADA
Buy
Turtle Beach price target raised to $26 from $23 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Turtle Beach to $26 and kept his Buy rating, saying the company's Q1 revenue and earnings beat were "extremely" encouraging. The analyst anticipated further sales upside for FY19 to come from more gaming publishers releasing "freemium" titles and a faster refresh cycle for Turtle Beach gaming accessory products.
04/09/19
DADA
04/09/19
NO CHANGE
Target $23
DADA
Buy
Turtle Beach can exploit secular gaming shift, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $23 price target on Turtle Beach after meeting with its CEO and CFO last week, saying the discussions increased his confidence that the company can "exploit the secular shifts in gaming" toward esports and the freemium model while generating "significant free cash flow". The analyst is also positive on the company's pending ROCCAT deal, which he expects to close in May, and "leverage both companies' relative geographic distribution strengths". Forte adds that the shift to freemium could be a catalyst for Turtle Beach in that gamers will have a larger budget to spend on gaming accessories by not having to pay for video games.
08/16/19
DADA
08/16/19
NO CHANGE
DADA
Buy
DA Davidson positive on Turtle Beach, Logitech after latest NPD gaming data
DA Davidson analyst Tom Forte keeps his Buy rating on Turtle Beach (HEAR) and Logitech (LOGI) with unchanged price targets of $26 and $58 respectively, saying investors should purchase the shares after the latest round of videogame industry data from NPD. The analyst notes that while accessory spending declined 12% in July, year-to-date spending is flat, which is "favorable" considering the tough comparison in the industry from last year's Fortnite craze. Forte further notes that Madden '20 was the best selling videogame in July and should be a catalyst for more headset sales given its "highly interactive" features.
GTLS Chart Industries
$67.76

1.625 (2.46%)

08/13/19
RAJA
08/13/19
UPGRADE
Target $72
RAJA
Outperform
Chart Industries upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Pavel Molchanov upgraded Chart Industries to Outperform from Market Perform with a $72 price target.
02/15/19
GABE
02/15/19
DOWNGRADE
GABE
Hold
Gabelli downgrades Chart Industries to Hold, says opportunity getting priced in
As previously reported, Gabelli analyst Matthew Trusz downgraded Chart Industries to Hold from Buy, noting that the stock has increased 2.6x since he recommended it in October 2016. With the opportunity looking "increasingly priced in," Trusz made "purely a valuation-driven decision" to downgrade the stock and would look to revisit his recommendation should the shares decline to the low-$70 range, he tells investors.
06/27/19
MSCO
06/27/19
INITIATION
Target $90
MSCO
Overweight
Chart Industries initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Connor Lynagh initiated Chart Industries with an Overweight rating and $90 price target, stating that he expects a "coming wave" of liquified natural gas export facility final investment decisions to drive strong orders for Chart over the next few years. The analyst, who projects Chart could realize $600M of order intake from "Big LNG" projects over the next 2 years, said upside could exist to that estimate if certain U.S. projects go forward.
03/22/19
CHLM
03/22/19
NO CHANGE
Target $117
CHLM
Buy
Chart Industries' LNG project wave has 'much more to come,' says Craig-Hallum
After Chart Industries announced it has booked a $135M equipment order for its Calcasieu Pass LNG export project, Craig-Hallum analyst Eric Stine said he thinks this is the start of more LNG project activity in the industry and for Chart, which he views as being "in a much better position than in past cycles." Stine, who expects LNG activity to accelerate and for Chart to be "a major participant," raised his price target on the stock to $117 from $107 and keeps a Buy rating on the shares.
NDRA Endra Life Sciences
$1.72

0.03 (1.78%)

06/13/19
DOTC
06/13/19
INITIATION
Target $5
DOTC
Buy
Endra Life Sciences initiated with a Buy at Dougherty
Dougherty analyst Kyle Bauser started Endra Life Sciences with a Buy rating and $5 price target.
05/20/19
LSCM
05/20/19
INITIATION
Target $7
LSCM
Buy
Endra Life Sciences initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Endra Life Sciences with a Buy rating and $7 price target. The company's next generation platform, Thermo Acoustic Enhanced Ultrasound, improves the common ultrasound with a radio frequency-based overlay to diagnose non- alcoholic fatty liver disease, O'Neil tells investors in a research note. He points out that NAFLD affects more than 1.4B people around the world. Further, he believes Endra's relationship with "ultrasound leader" GE Healthcare should speed up the company's commercialization.
07/15/19
HCWC
07/15/19
INITIATION
Target $6
HCWC
Buy
Endra Life Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino started Endra Life Sciences with a Buy rating and $6 price target. The analyst sees broad potential of the company's TAEUS platform to expand the utility of conventional ultrasound imaging. He recommends buying the shares ahead of the potential to gain CE Mark for TAEUS in the second half of 2019.
LTRX Lantronix
$3.42

-0.355 (-9.40%)

09/24/18
LSCM
09/24/18
NO CHANGE
Target $6
LSCM
Buy
Lantronix shares can see 'meaningful' multiple expansion, says Lake Street
Lake Street analyst Jaeson Schmidt believes Lantronix's equity offering last week gives the company "additional dry powder" to execute on its acquisition strategy. The analyst thinks the shares can see "meaningful" multiple expansion as investors gain confidence in the sustainability of the company's recent momentum. He reiterates a Buy rating on Lantronix with a $6 price target.
10/08/18
NEED
10/08/18
INITIATION
Target $5.5
NEED
Buy
Lantronix initiated with a Buy at Needham
Needham analyst Richard Valera initiated Lantronix with a Buy rating and a price target of $5.50, saying the company has reversed a trend of declining revenues since late 2015 under the leadership of its new CEO Jeff Benck. The analyst notes that the company is now growing and profitable, having ended FY18 on a strong note with a 9% revenue growth, as a result of new design wins in the Internet of Things realm along with its recent RFQ wins in IT management. Valera further states that if Lantronix can sustain its recent trajectory of improving sales and profitability, he sees shares rising even higher, adding that while some near term pressure related to China tariffs is possible, he sees those risks reflected in his valuation model.
REED Reed's
$1.65

-0.04 (-2.37%)

05/10/19
05/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wayfair (W) initiated with a Sell at Berenberg. 2. United Technologies (UTX) initiated with a Neutral at Seaport Global. 3. Alcon (ALC) initiated with an Outperform at Baird. 4. Pinterest (PINS) initiated with a Buy at Nomura Instinet and a Hold at Argus. 5. Reed's (REED) initiated with a Buy at RF Lafferty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/10/19
RFLF
05/10/19
INITIATION
Target $5
RFLF
Buy
Reed's initiated with a Buy at RF Lafferty
RF Lafferty analyst Roger Duan started Reed's with a Buy rating and $5 price target, citing the company's accelerating growth under new management, its leading position in craft beverages and its launch of several new products, including some with CBD.
04/26/19
LSCM
04/26/19
INITIATION
Target $6
LSCM
Buy
Reed's initiated with a Buy at Lake Street
Lake Street analyst Chris Krueger started Reed's with a Buy rating and $6 price target. The analyst believes the company is well positioned to take advantage of the "healthy consumer trend with its unique, handcrafted beverage products." Reed's will return to growth mode in 2019, with increasing margins, Krueger tells investors in a research note. He believes the company can grow sales annually at 20% for the next several years and could eventually become a takeout candidate for a larger beverage company. The stock should move higher as Reed's is awarded a growth multiple and revenues accelerate, contends Krueger.
04/26/19
04/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Vail Resorts (MTN) initiated with a Buy at SunTrust. 2. Tocagen (TOCA) initiated with an Overweight at Cantor Fitzgerald. 3. Dow Inc. (DOW) initiated with a Hold at Argus. 4. Gilead (GILD) initiated with an Outperform at Bernstein. 5. Reed's (REED) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RIBT RiceBran
$2.67

0.02 (0.75%)

11/07/18
LSCM
11/07/18
NO CHANGE
Target $5
LSCM
Buy
RiceBran price target raised to $5 from $4 at Lake Street
Lake Street analyst Chris Krueger noted that RiceBran's Q3 results met expectations, but "importantly" the company announced its option to acquire Golden Ridge's rice mill was exercised, which doubles its revenue outlook for 2019. A larger rice crop currently being harvested as well as mill ownership should clear up the weak rice bran supply issues that hurt sales and margins in 2018, said Krueger, who raised his price target on RiceBran shares to $5 and keeps a Buy rating on the stock.
RST Rosetta Stone
$19.64

0.95 (5.08%)

03/07/19
BRRR
03/07/19
NO CHANGE
Target $27
BRRR
Outperform
Rosetta Stone price target raised to $27 from $24 at Barrington
Barrington analyst Alexander Paris raised his price target for Rosetta Stone to $27 following the company's better than expected Q4 results and 2019 guidance. Rosetta's transition to a subscription model is now complete and its improving operating metrics will become clearer to investors, Paris tells investors in a post-earnings research note. He points out that the company's sales and revenue growth will return in 2019 after three consecutive down years, with management's guidance calling for double-digit GAAP revenue growth and bookings growth in 2019. The analyst continues to recommend buying Rosetta Stone shares based on the intrinsic value of its parts. He reiterates an Overweight rating on the name.
11/07/18
LSCM
11/07/18
NO CHANGE
Target $21
LSCM
Buy
Rosetta Stone price target raised to $21 from $18 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Rosetta Stone to $21 saying he likes 11% total Q3 Sales growth, ex-SOURCENEXT, and the company's odds of growing sales "meaningfully" in 2019, driven by new products. The analyst keeps a Buy rating on Rosetta Stone.
05/08/19
LSCM
05/08/19
NO CHANGE
Target $26
LSCM
Buy
Rosetta Stone price target raised to $26 from $21 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Rosetta Stone to $26 from $21 following the company's "solid" Q1 results. The analyst keeps a Buy rating on the shares.
03/07/19
BRRR
03/07/19
NO CHANGE
Target $27
BRRR
Outperform
Rosetta Stone price target raised to $27 from $24 at Barrington
Barrington analyst Alexander Paris, Jr. reiterated an Outperform rating on Rosetta Stone and raised his price target to $27 from $24 following the company's better than expected Q4 results. In a research note to investors, the analyst says he would continue to be a buyer of Rosetta given the intrinsic value of its parts, continued strong growth at Lexia, which has been driven by a bookings CAGR of 26% since 2014, a more predictable/sustainable sales model as a result of the subscription transition, which will continue to benefit from sales team alignment as the company executes on its top-down and bottom-up go-to-market strategy; improving cash flow, and its already healthy balance sheet with no long-term debt.
TRUP Trupanion
$26.87

1.58 (6.25%)

08/16/19
CHLM
08/16/19
DOWNGRADE
CHLM
Hold
Trupanion downgraded to Hold from Buy at Craig-Hallum
06/26/19
GUGG
06/26/19
NO CHANGE
GUGG
Buy
Trupanion fine in Washington removes an overhang, says Guggenheim
After the Washington State Office of the Insurance Commissioner ordered Trupanion to pay $100,000 to settle disputes, Guggenheim analyst David Westenberg said he believes the fine was already paid, that the company will license the five of eight reps in Washington that had not yet been licensed and that it will stop using Review.com. While the ruling does leave the potential for other states to follow suit, the fine is "manageable" and removes an overhang, according to Westenberg. The analyst, who keeps a Buy rating on Trupanion shares, added that he was pleased to see Washington state confirm it approves of territory partners and exam day offers, which he calls "two key Trupanion competitive advantages that shorts attack."
08/16/19
CHLM
08/16/19
DOWNGRADE
Target $29
CHLM
Hold
Trupanion downgraded to Hold at Craig-Hallum, price target cut to $29
Craig-Hallum analyst Kevin Ellich downgraded Trupanion to Hold from Buy and lowered his price target to $29 from $38, saying he has some growing concerns about deteriorating operating metrics, including the total addressable market for pet insurance, and the competitive landscape. Ellich says that while there is little question that the animal health industry, especially the pet market, has a number of tailwinds, he believes deterioration in some of Trupanion's key operating metrics signal the pet insurance market is getting more challenging and growth could slow over the next several quarters.
06/26/19
LSCM
06/26/19
NO CHANGE
Target $46
LSCM
Buy
Lake Street says Trupanion settlement in Washington 'insignificant'
After the State of Washington Office of Insurance Commissioner filed a consent order on June 24 detailing Trupanion's agreement to a settlement and to pay a $100,000 fine, Lake Street analyst Mark Argento said he views the rulings and fine as "insignificant, especially compared to the amount of attention some have given this investigation." He doesn't expect any material impact to the business going forward and believes other states have looked at the same items and have not taken issue. He continues to identify Trupanion as one of his favorite long-term growth stories and keeps a Buy rating on the shares with a $46 price target.
TLRA Telaria
$9.94

0.14 (1.43%)

05/10/19
LSCM
05/10/19
NO CHANGE
Target $11
LSCM
Buy
Telaria price target raised to $11 from $7 at Lake Street
Lake Street analyst Mark Argento yesterday raised his price target for Telaria to $11 from $7 following the company's better than expected Q1 results. The reorganization of the salesforce undertaken in Q3 has ramped faster than anticipated, Argento told investors in a research note. He believes Telaria's growth story is in the early innings and reiterates a Buy rating on the shares.
04/09/19
ADAM
04/09/19
NO CHANGE
Target $9
ADAM
Buy
Telaria price target raised to $9 from $6 at Canaccord
Canacord analyst Austin Moldow maintained a Buy rating on Telaria and raised his price target to $9 from $6, saying that it has been a year and half since Telaria restructured and renamed and, based on recent meetings, it seems that investors are "giving it a leg up in sentiment." Moldow says he has also come away more confident, and continues to view the stock favorable based on industry tailwinds, company positioning and M&A potential.
02/27/19
LSCM
02/27/19
NO CHANGE
Target $7
LSCM
Buy
Telaria price target raised to $7 from $6 at Lake Street
Lake Street analyst Mark Argento raised his price target for Telaria to $7 saying "strong" same store sales and new partnerships drove the company's growth in Q4. The analyst sees a "long runway ahead" for Telaria's growth and keeps a Buy rating on the shares.
01/23/19
CHLM
01/23/19
NO CHANGE
Target $5
CHLM
Buy
Telaria shares well positioned after Hulu extension, says Craig-Hallum
Telaria (TLRA) and Hulu have announced a renewed relationship, extending the duration an additional two years while layering in incremental developmental work to provide unique ad units and enhanced real-time monetization controls, Craig-Hallum analyst Jason Kreyer tells investors in a research note. The analyst believes the evolution of Hulu's advertising services is more likely to drive improved profitability and scale to Telaria than an inflection of revenue. He thinks Telaria shares are positioned well for 2019 and maintains a Buy rating on the shares with a $5 price target.
ZIOP Ziopharm
$4.92

0.15 (3.14%)

04/04/19
LSCM
04/04/19
INITIATION
Target $7
LSCM
Buy
Ziopharm initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten started Ziopharm with a Buy rating and $7 price target. "By unlocking the potential of its Sleeping Beauty technology," Ziopharm is poised to "deliver a leap forward" in the personalization of cancer therapy, Flaten tells investors in a research note. The analyst sees an opportunity for "significant value generation" with near-term clinical catalysts.
08/22/19
RAJA
08/22/19
INITIATION
Target $6.5
RAJA
Outperform
Ziopharm resumed with an Outperform at Raymond James
Raymond James analyst David Novak resumed Ziopharm with an Outperform rating and $6.50 price target.
08/23/19
08/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aramark (ARMK) initiated with an Outperform at Oppenheimer. 2. Repligen (RGEN) resumed with an Overweight at Stephens. 3. Ziopharm (ZIOP) resumed with an Outperform at Raymond James. 4. Occidental Petroleum (OXY) reinstated with a Hold at Jefferies. 5. PacWest Bancorp (PACW) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
LDLW
04/01/19
INITIATION
Target $7.5
LDLW
Buy
Ziopharm initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen initiated ZipPharm with a Buy and $7.50 price target.
WPRT Westport
$3.03

0.18 (6.32%)

05/10/19
LSCM
05/10/19
UPGRADE
LSCM
Buy
Westport upgraded to Buy from Hold at Lake Street
Lake Street analyst Robert Brown upgraded Westport Fuel Systems to Buy from Hold saying the company's "better" Q1 provides confidence in its execution.
05/10/19
LSCM
05/10/19
UPGRADE
Target $5
LSCM
Buy
Lake Street upgrades Westport to Buy on improving fundamentals
Lake Street analyst Robert Brown upgraded Westport Fuel Systems to Buy from Hold with an unchanged price target of $5. The strength in the HPDI ramp with Volvo provides increased confidence that the management transition has gone smoothly, Brown tells investors in a research note. While the outcome of the FCPA investigation remains a risk, Westport's fundamentals appear to be improving and 2019 should be an inflection year, adds the analyst.
02/05/19
LSCM
02/05/19
DOWNGRADE
LSCM
Hold
Westport downgraded to Hold from Buy at Lake Street
02/05/19
02/05/19
DOWNGRADE
Target $5

Hold
Lake Street downgrades Westport to Hold amid 'cloud of uncertainty'
As previously reported, Lake Street analyst Robert Brown downgraded Westport Fuel Systems to Hold from Buy, stating that the abrupt resignation of CFO Mike Willis following the changeover of CEO in January "creates a cloud of uncertainty." While he still views 2019 as an inflection year for Westport, citing expectations for the Volvo HPDI program and the Weichai HPDI engine launches, Brown said he needs time to gain confidence in the company's execution following the management changes. He lowered his price target on Westport shares to $5 from $6 and said he believes shares will be range-bound in the near-term.
SONM Sonim
$3.75

(0.00%)

09/11/19
OPCO
09/11/19
NO CHANGE
Target $6
OPCO
Outperform
Sonim price target lowered to $6 from $18 at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz lowered his price target for Sonim to $6 from $18 as a large new customer lowered sales forecasts, delayed subsidies, and has been slower than expected in stocking retail locations. Additionally, the analyst notes that the company experienced technical challenges in both the XP8 smartphone and accessory-related issues in its feature phones. Finally, working through these issues has slowed down rollouts to smaller carrier customers, he adds, highlighting that sales momentum has slowed and guidance was significantly cut. He reiterates an Outperform rating on the shares.
07/18/19
RILY
07/18/19
INITIATION
RILY
B. Riley FBR starts Sonim at Buy on rugged mobile device growth
B. Riley FBR analyst Zack Silver earlier today initiated coverage of Sonim Technologies with a Buy rating and $17 price target. The stock in morning trading is down 11c to $13.64. The analyst believes Sonim will continue to capture rugged mobile device market share in the U.S. and Canada, and that government agencies and industrial firms will continue to replace "cumbersome" legacy devices built for land mobile radio networks in exchange for mobile devices built for commercial long term evolution networks. This will drive overall rugged mobile device market expansion, Silver writes in a research note. He believes these two levers alone are enough to drive mid-20% annual revenue growth and mid-50% annual EBITDA growth over the next several years for Sonim.
07/25/19
LSCM
07/25/19
NO CHANGE
Target $19
LSCM
Buy
Sonim results reinforce 'strong growth story,' says Lake Street
Lake Street analyst Jaeson Schmidt believes Sonim Technologies' "solid" Q2 results reinforce the company's "strong growth story." He thinks investors will find a lot to like in the report as revenue came in above estimates, the midpoint of Q3 revenue guidance was better, and the midpoints of revenue and adjusted EBITDA margin for the full year beat expectations. The analyst continues to believe the Sonim can grow 25%-plus in each of the next three years. Schmidt reiterates a Buy rating on the shares with a $19 price target.
07/18/19
07/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sysco (SYY) initiated with an Underweight at Consumer Edge. 2. Sonim (SONM) initiated with a Buy at B. Riley FBR. 3. Ingevity (NGVT) initiated with an Outperform at BMO Capital. 4. Clarivate Analytics (CCC) initiated with a Neutral at Citi. 5. Photronics (PLAB) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PERI Perion Network
$5.33

0.03 (0.57%)

07/08/19
LSCM
07/08/19
INITIATION
Target $6
LSCM
Buy
Perion Network initiated with a Buy at Lake Street
Lake Street analyst Eric Martinuzzi started Perion Network with a Buy rating and $6 price target. Perion is an underappreciated advertising technology company that has repaired its balance sheet and is on the cusp of growth, Martinuzzi tells investors in a research note. He believes the shares are "mispriced" and expects sales growth in 2020 to raise the company's profile.
PFIE Profire Energy
$1.66

0.07 (4.40%)

07/08/19
AGIS
07/08/19
INITIATION
Target $3.5
AGIS
Buy
Profire Energy initiated with a Buy at Aegis
Aegis analyst James Jang initiated Profire Energy with a Buy rating and $3.50 price target.
03/12/19
CHDN
03/12/19
DOWNGRADE
CHDN
Neutral
Profire Energy downgraded to Neutral from Buy at Chardan
INTT inTEST
$4.55

-0.02 (-0.44%)

12/28/18
DAWS
12/28/18
INITIATION
Target $10
DAWS
Buy
inTEST initiated with a Buy at Dawson James
Dawson James analyst Barry Sine initiated inTest with a Buy and $10 price target.
02/08/19
LSCM
02/08/19
INITIATION
Target $9
LSCM
Buy
inTEST initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started inTEST with a Buy rating and $9 price target. The analyst believes investors do not fully appreciate how the company's 2017 acquisition of Ambrell increased its total addressable market, diversified revenue away from the more volatile semiconductor market, added scale, and positioned it for sustained growth. With a new annual addressable market of $620M, inTEST has a long runway for growth and should be able to achieve its long-term goal of $150M in revenue, Schmidt tells investors in a research note.
HSC Harsco
$20.07

1.22 (6.47%)

10/31/18
LSCM
10/31/18
NO CHANGE
LSCM
Harsco price target raised to $33 from $31 at Lake Street
Lake Street analyst Robert Brown reiterated a Buy rating on Harsco and raised his price target on shares to $33 from $31 following the company's "excellent" Q3 results. The analyst believes Harsco is seeing the results from its turnaround efforts and is benefitting from a recovery in the industrial and rail end markets, and is now shifting to growth mode, adding new contracts and expanding commercial efforts. Brown said the integration of the recent ALTEK acquisition is on track and he expects additional acquisitions in 2019.
02/21/19
LSCM
02/21/19
NO CHANGE
Target $33
LSCM
Buy
Harsco has opportunity to reach 'mid-$40's' if targets hit, says Lake Street
After Harsco management increased their long-term targets to $2.5B in revenue and $500M in EBITDA in 2021, up from $2B and $400M, Lake Street analyst Robert Brown attributed the guidance hike partially to an improving macro environment but also said it reflects results from the growth initiatives the company has undertaken. If the company can reach its 2021 targets, he estimates "a stock opportunity in the mid-$40's," said Brown, who keeps a Buy rating on Harsco shares with a $33 price target.
07/26/19
LSCM
07/26/19
NO CHANGE
Target $36
LSCM
Buy
Harsco price target raised to $36 from $33 at Lake Street
Lake Street analyst Robert Brown raised his price target for Harsco to $36 from $33 citing the sale of Air-X and the acquisition of Clean Earth. Harsco should now have much lower cyclicality, lower capital intensity, and better growth, Brown tells investors in a research note. He believes the Street continues to underappreciate Harsco's operating and strategic improvements. The analyst reiterates a Buy rating on the shares.
OCX OncoCyte
$1.79

0.11 (6.55%)

09/05/19
PIPR
09/05/19
NO CHANGE
PIPR
OncoCyte acquisition of Razor Genomics stake 'smart,' says Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating and $5.40 price target on OncoCyte after the company announced it was acquiring a 25% stake in Razor Genomics for $10M, with an option to buy the entire company for a value of around $33M, which Quirk called a "smart deal... consistent with OncoCyte's long-term view of menu expansion." Additionally, the analyst was positive as OncoCyte reiterated it was close to restarting the CLIA Clinical Validation process for DetermaVu.
06/27/19
BNCH
06/27/19
NO CHANGE
Target $7
BNCH
Buy
OncoCyte reaction to DetermaVu delay overdone, says Benchmark
Benchmark analyst Bruce Jackson said that he views yesterday's price action in shares of OncoCyte after the company announced that it needs additional time to complete the CLIA validation study as overdone. The validation process could be converted to an automated one, said the company, which Jackson would view as a positive since it tends to improve overall test performance by removing a source of variability. Jackson, who said he doesn't view the announcement of the delay for the DetermaVu test as a major setback for OncoCyte, sees the associated pullback as a buying opportunity and keeps a Buy rating and $7 price target on the shares.
07/03/19
BNCH
07/03/19
NO CHANGE
BNCH
Speculative Buy
BioTime sale of OncoCyte shares expands shareholder base, says Benchmark
Benchmark analyst Bruce Jackson noted that OncoCyte's (OCX) majority shareholder, BioTime (BTX), is selling 2.25M of its 14.7M shares in the former. He views the share sale as positive for both, noting that BioTime will gain additional capital and OncoCyte will gain a broader shareholder base. BioTime will still hold about 24% of OncoCyte's stock following the deal's completion and Broadwood Partners will be building on its 15.6% stake by acquiring about 1M of the 2.25M shares being offered, noted Jackson, who keeps a Speculative Buy rating on OncoCyte shares.
08/15/19
PIPR
08/15/19
NO CHANGE
PIPR
OncoCyte delayed DetermaVu study by 6-9 months, says Piper Jaffray
OncoCyte management said last night that the CLIA Validation study for DetermaVu will be delayed 6-9 months from now following inconsistencies with the RNA extraction reagents used in the workflow, which was impacting reproducibility of the data, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst pushed out his assumptions for reimbursement and commercialization by six months and lowered his price target for the shares to $5.40 from $6. His new model assumes commercialization in Q3 of 2020 and reimbursement beginning in Q3 of 2021. Quirk keeps an Overweight rating on he shares.
SHSP SharpSpring
$11.84

0.01 (0.08%)

08/08/19
SPHN
08/08/19
UPGRADE
Target $13
SPHN
Overweight
SharpSpring upgraded to Overweight from Equal Weight at Stephens
Stephens analyst James Rutherford upgraded SharpSpring to Overweight from Equal Weight and raised his price target for the shares to $13 from $11.
07/29/19
SPHN
07/29/19
INITIATION
Target $11
SPHN
Equal Weight
SharpSpring initiated with an Equal Weight at Stephens
Stephens analyst James Rutherford started SharpSpring with an Equal Weight rating and $11 price target, stating that its product has "great features, a low price point...and rave customer reviews," but he sees issues with its high churn and poor unit economics. Though the shares trade at a discount to peers, he would prefer to see if SharpSpring's initiatives improve retention before he get more positive on the stock, the analyst said.
07/18/19
ADAM
07/18/19
NO CHANGE
Target $16
ADAM
Buy
SharpSpring price target lowered to $16 from $22 at Canaccord
Canaccord analyst David Hynes lowered his price target on SharpSpring to $16 from $22 following Q2 results. The analyst said customer additions and expected ARR fell short of expectations. He said the shortfall comes as a surprise given the recent business momentum but he continues to believe the company is competing with a robust product and disruptive pricing in the agency market which should give it a multi-year un rate of 20%+ growth and improving profitability. Hynes reiterated his Buy rating on SharpSpring shares.
08/08/19
SPHN
08/08/19
UPGRADE
Target $13
SPHN
Overweight
Stephens upgrades SharpSpring to Overweight less than two weeks after initiation
As previously reported, Stephens analyst James Rutherford upgraded SharpSpring to Overweight from Equal Weight and raised his price target for the shares to $13 from $11 after making a "few key changes" to his assumptions. Noting this appears to be an "abrupt change in view" after having initiated coverage of the stock with an Equal-Weight rating just a week and a half ago, Rutherford explained that his revised rating comes after he spent more time digging into unit economics. He previously was forecasting about 60% annual logo churn and around 35% net revenue churn, but he now estimates logo churn of 30%-35% and annual net revenue churn of 20%-25%, said Rutherford.
SLGG Super League Gaming
$4.75

0.395 (9.08%)

03/18/19
NORL
03/18/19
INITIATION
NORL
Outperform
Super League Gaming initiated with an Outperform at Northland
Northland analyst Michael Latimore with an Outperform and $15 price target.
03/11/19
NATL
03/11/19
INITIATION
Target $15
NATL
Buy
Super League Gaming initiated with a Buy at National Securities
National Securities analyst Ilya Grozovsky initiated Super League Gaming with a Buy and $15 price target saying the company is addressing a greenfield opportunity in amateur e-sports. Grozovsky believes Super League Gaming is an effective way to participate in the multi-year growth of e-sports as it quickly has become a rival to traditional sports.
03/18/19
03/18/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Western Asset Mortgage (WMC) initiated with a Market Perform at Keefe Bruyette. 2. Cars.com (CARS) initiated with a Neutral at Goldman Sachs. 3. Super League Gaming (SLGG) initiated with an Outperform at Northland. 4. Arcus Biosciences (RCUS) initiated with a Buy at BTIG, while Momenta (MNTA) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
LSCM
03/25/19
INITIATION
Target $15
LSCM
Buy
Super League Gaming initiated with a Buy at Lake Street
Lake Street analyst Mark Argento started Super League Gaming with a Buy rating and $15 price target. The company's platform is "taking competitive amateur video gaming out of the basement and into organized, social events that bring amateur esports participants together with gaming and consumer brands to create a unique media and entertainment experience," Argento tells investors in a research note. He expects Super League's business to achieve scale over the next three years.

TODAY'S FREE FLY STORIES

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change  »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated  »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.